Breaking News

Amgen Appoints CFO

June 10, 2014

Meline to head finance and investor relations operations

David W. Meline has been appointed executive vice president and chief financial officer of Amgen, effective July 21. He will be responsible for Amgen's finance and investor relations operations, reporting to Robert A. Bradway, chairman and chief executive officer. Mr. Meline succeeds Michael A. Kelly, who served as acting CFO since January 2014.
 
Mr. Meline joins the company from 3M, where he most recently served as senior vice president and chief financial officer, responsible for all financial activities for 3M across 70 countries. Previously, he held several leadership roles at General Motors, working on five continents during his tenure.
 
Mr. Bradway said, "David's leadership talent and broad international experience will be invaluable to Amgen as we execute our strategy for long term growth and bring our pipeline of medicines toward commercialization in a number of new markets. I am delighted to welcome him to the team."
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks